{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:19Z","timestamp":1740144079359,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40268-022-00410-6","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T16:03:30Z","timestamp":1671638610000},"page":"43-53","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Randomised Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Palovarotene Ophthalmic Solution"],"prefix":"10.1007","volume":"23","author":[{"given":"William J.","family":"Foster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L.","family":"Strahs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kent W.","family":"Small","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Roach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"key":"410_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jtos.2017.05.005","volume":"15","author":"JD Nelson","year":"2017","unstructured":"Nelson JD, Craig JP, Akpek EK, Azar DT, Belmonte C, Bron AJ, et al. TFOS DEWS II Introduction Ocul Surf. 2017;15:269\u201375.","journal-title":"TFOS DEWS II Introduction. Ocul Surf."},{"key":"410_CR2","doi-asserted-by":"crossref","unstructured":"The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:93\u2013107. https:\/\/pubmed.ncbi.nlm.nih.gov\/17508117\/.","DOI":"10.1016\/S1542-0124(12)70082-4"},{"key":"410_CR3","first-page":"71","volume":"112","author":"EM Messmer","year":"2015","unstructured":"Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112:71\u201382.","journal-title":"Dtsch Arztebl Int"},{"key":"410_CR4","doi-asserted-by":"crossref","unstructured":"Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:163\u201378. https:\/\/pubmed.ncbi.nlm.nih.gov\/17508120\/.","DOI":"10.1016\/S1542-0124(12)70085-X"},{"key":"410_CR5","first-page":"192","volume":"6","author":"M-A Javadi","year":"2011","unstructured":"Javadi M-A, Feizi S. Dry eye syndrome. J Ophthalmic Vis Res. 2011;6:192\u20138.","journal-title":"J Ophthalmic Vis Res"},{"key":"410_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/ICU.0000000000000569","volume":"30","author":"EC O'Neil","year":"2019","unstructured":"O\u2019Neil EC, Henderson M, Massaro-Giordano M, Bunya VY. Advances in dry eye disease treatment. Curr Opin Ophthalmol. 2019;30:166\u201378.","journal-title":"Curr Opin Ophthalmol"},{"key":"410_CR7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jtos.2020.11.012","volume":"19","author":"GD Novack","year":"2020","unstructured":"Novack GD. Repurposing medications. Ocul Surf. 2020;19:336\u201340.","journal-title":"Ocul Surf"},{"key":"410_CR8","doi-asserted-by":"crossref","first-page":"251584141987036","DOI":"10.1177\/2515841419870366","volume":"11","author":"SL Haber","year":"2019","unstructured":"Haber SL, Benson V, Buckway CJ, Gonzales JM, Romanet D, Scholes B. Lifitegrast: a novel drug for patients with dry eye disease. Ther Adv Ophthalmol. 2019;11:2515841419870366.","journal-title":"Ther Adv Ophthalmol."},{"key":"410_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/aos.13436","volume":"96","author":"C Baudouin","year":"2018","unstructured":"Baudouin C, Irke\u00e7 M, Messmer EM, Ben\u00edtez-del-Castillo JM, Bonini S, Figueiredo FC, ODISSEY European Consensus Group Members, et al. Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting. Acta Ophthalmol. 2018;96:111\u20139.","journal-title":"Acta Ophthalmol"},{"key":"410_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2147\/OPTH.S189039","volume":"13","author":"M Taylor","year":"2019","unstructured":"Taylor M, Ousler G, Torkildsen G, Walshe C, Fyfe MCT, Rowley A, et al. A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease. Clin Ophthalmol. 2019;13:261\u201375.","journal-title":"Clin Ophthalmol"},{"key":"410_CR11","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2147\/OPTH.S233194","volume":"14","author":"DE White","year":"2020","unstructured":"White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A. Treatment satisfaction among patients using anti-inflammatory topical medications for dry eye disease. Clin Ophthalmol. 2020;14:875\u201383.","journal-title":"Clin Ophthalmol"},{"key":"410_CR12","first-page":"1641","volume":"13","author":"H Nezzar","year":"2007","unstructured":"Nezzar H, Chiambaretta F, Marceau G, Blanchon L, Faye B, Dechelotte P, Rigal D, Sapin V. Molecular and metabolic retinoid pathways in the human ocular surface. Mol Vis. 2007;13:1641\u201350.","journal-title":"Mol Vis"},{"issue":"Suppl. 1","key":"410_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/01.icu.0000512373.81749.b7","volume":"27","author":"MS Milner","year":"2017","unstructured":"Milner MS, Beckman KA, Luchs JI, Allen QB, Awdeh RM, Berdahl J, et al. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders: new strategies for diagnosis and treatment. Curr Opin Ophthalmol. 2017;27(Suppl. 1):3\u201347.","journal-title":"Curr Opin Ophthalmol"},{"key":"410_CR14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ajo.2008.08.015","volume":"147","author":"EC Kim","year":"2009","unstructured":"Kim EC, Choi JS, Joo CK. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol. 2009;147:206-13.e203.","journal-title":"Am J Ophthalmol"},{"key":"410_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1159\/000310829","volume":"211","author":"TK Kobayashi","year":"1997","unstructured":"Kobayashi TK, Tsubota K, Takamura E, Sawa M, Ohashi Y, Usui M. Effect of retinol palmitate as a treatment for dry eye: a cytological evaluation. Ophthalmologica. 1997;211:358\u201361.","journal-title":"Ophthalmologica"},{"key":"410_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/112067210001000205","volume":"10","author":"H Selek","year":"2000","unstructured":"Selek H, Unl\u00fc N, Orhan M, Irke\u00e7 M. Evaluation of retinoic acid ophthalmic emulsion in dry eye. Eur J Ophthalmol. 2000;10:121\u20137.","journal-title":"Eur J Ophthalmol"},{"key":"410_CR17","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0161-6420(85)33968-4","volume":"92","author":"SC Tseng","year":"1985","unstructured":"Tseng SC, Maumenee AE, Stark WJ, Maumenee IH, Jensen AD, Green WR, et al. Topical retinoid treatment for various dry-eye disorders. Ophthalmology. 1985;92:717\u201327.","journal-title":"Ophthalmology"},{"key":"410_CR18","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00109-015-1289-8","volume":"93","author":"K Kimura","year":"2015","unstructured":"Kimura K, Orita T, Liu Y, Yang Y, Tokuda K, Kurakazu T, et al. Attenuation of EMT in RPE cells and subretinal fibrosis by an RAR-\u03b3 agonist. J Mol Med. 2015;93:749\u201358.","journal-title":"J Mol Med"},{"key":"410_CR19","first-page":"1368","volume":"21","author":"Y Liu","year":"2015","unstructured":"Liu Y, Kimura K, Orita T, Suzuki K, Teranishi S, Mori T, Sonoda K-H. Inhibition by a retinoic acid receptor \u03b3 agonist of extracellular matrix remodeling mediated by human Tenon fibroblasts. Curr Opin Ophthalmol. 2015;21:1368\u201377.","journal-title":"Curr Opin Ophthalmol"},{"key":"410_CR20","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.ophtha.2007.06.047","volume":"114","author":"RW Beck","year":"2007","unstructured":"Beck RW, Maguire MG, Bressler NM, Glassman AR, Lindblad AS, Ferris FL. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology. 2007;114:1804\u20139.","journal-title":"Ophthalmology"},{"key":"410_CR21","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","volume":"15","author":"JS Wolffsohn","year":"2017","unstructured":"Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al. TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017;15:539\u201374.","journal-title":"Ocul Surf"},{"key":"410_CR22","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2147\/OPTH.S226168","volume":"13","author":"DE White","year":"2019","unstructured":"White DE, Zhao Y, Ogundele A, Fulcher N, Acs A, Moore-Schiltz L, et al. Real-world treatment patterns of cyclosporine ophthalmic emulsion and Lifitegrast ophthalmic solution among patients with dry eye. Clin Ophthalmol. 2019;13:2285\u201392.","journal-title":"Clin Ophthalmol"},{"key":"410_CR23","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jtos.2017.08.003","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15:802\u201312.","journal-title":"Ocul Surf"},{"key":"410_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000501374","volume":"62","author":"C Cursiefen","year":"2019","unstructured":"Cursiefen C, Cordeiro F, Cunha-Vaz J, Wheeler-Schilling T, Scholl HPN. Unmet needs in ophthalmology: a European Vision Institute-Consensus Roadmap 2019\u20132025. Ophthalmic Res. 2019;62:123\u201333.","journal-title":"Ophthalmic Res"},{"key":"410_CR25","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.37765\/ajmc.2021.88625","volume":"27","author":"JD Dunn","year":"2021","unstructured":"Dunn JD, Karpecki PM, Meske ME, Reissman D. Evolving knowledge of the unmet needs in dry eye disease. Am J Manag Care. 2021;27:S23-32.","journal-title":"Am J Manag Care"},{"key":"410_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/bjophthalmol-2015-307415","volume":"100","author":"C Baudouin","year":"2016","unstructured":"Baudouin C, Messmer EM, Aragona P, Geerling G, Akova YA, Ben\u00edtez-del-Castillo J, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;100:300\u20136.","journal-title":"Br J Ophthalmol"},{"key":"410_CR27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2165\/00002018-199309040-00006","volume":"9","author":"CM Mills","year":"1993","unstructured":"Mills CM, Marks R. Adverse reactions to oral retinoids. Drug Saf. 1993;9:280\u201390.","journal-title":"Drug Saf"},{"key":"410_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.det.2007.02.002","volume":"25","author":"A Desai","year":"2007","unstructured":"Desai A, Kartono F, Del Rosso JQ. Systemic retinoid therapy: a status report on optimal use and safety of long-term therapy. Dermatol Clin. 2007;25:185\u201393.","journal-title":"Dermatol Clin"},{"key":"410_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2147\/CLEP.S146397","volume":"10","author":"ML Bell","year":"2018","unstructured":"Bell ML, Whitehead AL, Julious SA. Guidance for using pilot studies to inform the design of intervention trials with continuous outcomes. Clin Epidemiol. 2018;10:153\u20137.","journal-title":"Clin Epidemiol"},{"key":"410_CR30","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0002-9394(03)00218-6","volume":"136","author":"DA Schaumberg","year":"2003","unstructured":"Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318\u201326.","journal-title":"Am J Ophthalmol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-022-00410-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-022-00410-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-022-00410-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T08:29:28Z","timestamp":1677918568000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-022-00410-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["410"],"URL":"https:\/\/doi.org\/10.1007\/s40268-022-00410-6","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"type":"print","value":"1174-5886"},{"type":"electronic","value":"1179-6901"}],"subject":[],"published":{"date-parts":[[2022,12,21]]},"assertion":[{"value":"15 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Ipsen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"WJF is a consultant for Altasciences. ALS is an employee of Ipsen. KWS has no financial disclosures. JMR was an employee of Ipsen at the time the study was conducted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Qualified researchers may request access to patient-level study data that underlie the results reported in this publication. Additional relevant study documents, including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan and dataset specifications may also be made available. Patient-level data will be anonymised and study documents will be redacted to protect the privacy of study participants. Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the USA and European Union or after the primary manuscript describing the results has been accepted for publication, whichever is later. Further details on Ipsen\u2019s sharing criteria, eligible studies and process for sharing are available here (). Any requests should be submitted to  for assessment by an independent scientific review board.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Substantial contributions to study conception and design: WJF, ALS, JMR; substantial contributions to analysis and interpretation of the data: WJF, ALS, KWS, JMR; drafting the article or revising it critically for important intellectual content: WJF, ALS, KWS, JMR; final approval of the version of the article to be published: WJF, ALS, KWS, JMR.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"Not applicable.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Sharing"}}]}}